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Editorial: endoscopic inflammation in ileoanal pouches—does it 
really matter? Authors' reply
We thank Drs. Townsend and Subramanian for their interest in our 
study and appreciate their comments regarding endoscopic healing 
in pouch patients.1,2 As noted in our discussion, we acknowledge 
the inherent limitations of our study including its retrospective na‐
ture, potential selection bias and lack of standardised endoscopic 
surveillance protocol. However, we think the results of our study 
still provide a novel observation regarding the prognostic impor‐
tance of endoscopic activity in asymptomatic pouch patients. We 
think that acute pouchitis is a meaningful clinical outcome that im‐
pacts patients' quality of life with increasing evidence that some 
interventions (probiotics, dietary interventions) may decrease 
its occurrence. We agree that chronic pouchitis and pouch fail‐
ure would be even more impactful outcomes; however, the over‐
all number of patients with these events was low in our cohort. 
In addition, it is difficult to compare the relative performance of 
endoscopic findings with faecal calprotectin (FC) across studies, 
and such a comparison would require a study in which both endo‐
scopic and FC data are available. We agree that prospective studies 
with protocolised pouch surveillance are needed to further define 
the importance (and attainability) of endoscopic healing in pouch 
patients.
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Editorial: rapid disease progression in hepatitis delta—can we 
turn the tide?
Palom et al recently reported the results of a long‐term follow‐up 
study of patients with chronic hepatitis delta (HDV) enrolled from 
four academic hospitals in Spain.1 Their findings illustrate some of 
the major challenges we face in the management of this deadly dis‐
ease. First, patients with HDV typically present with low HBV DNA 
levels and with minimally elevated ALT, thus masquerading as inac‐
tive HBV carriers. A high index of suspicion is therefore required 
to prevent underdiagnosis.2,3 This is especially important given the 
rapid disease progression of HBV‐HDV co‐infection. In the recent 
study, 30% of patients had cirrhosis at study entry, and 31% of 
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non‐cirrhotic patients developed cirrhosis during follow‐up. Sadly, 
these rates are similar to those reported in a cohort that enrolled 
patients from 1997 onwards.4 Importantly, achievement of HDV 
RNA undetectability reduced the risk of progression to cirrhosis 
and improved survival, but did not reduce the risk of hepatocellular 
carcinoma (HCC). This is in line with studies of successfully treated 
patients with HBV or HCV cirrhosis, where HCC risk also remains 
considerable.5,6
At this time, (pegylated‐)interferon ((PEG‐)IFN) is the only 
treatment option for HDV. Treatment results in HDV RNA nega‐
tivity in 30% of patients, but relapse rates are high and this can‐
not be prevented through adding tenofovir.7,8 Response to (PEG‐)
IFN (defined as undetectable HDV RNA) has been shown to de‐
crease the risk of liver‐related morbidity.9 In the current study, 
(PEG‐)IFN was also associated with an improved prognosis, irre‐
spective of HDV RNA response. Given the retrospective nature 
of this study, this finding should be interpreted with caution, as 
patients who received therapy may have had less advanced dis‐
ease, and since inclusion of patients with a history of (PEG‐)IFN 
therapy may have introduced bias. Finally, it appears that (PEG‐)
IFN therapy was not analysed as a time‐varying covariate, which 
may also have influenced results. It therefore remains uncer‐
tain whether (PEG‐)IFN treatment confers survival benefits in 
non‐responders.
Given the low success rates with currently available ther‐
apies, identification of patients at highest risk for adverse 
outcomes remains important for patient management and coun‐
selling. In this study, a previously described baseline‐event‐an‐
ticipation (BEA) score was applied to predict outcomes during 
follow‐up. There was a clear relationship between higher BEA 
scores and risk of liver‐related events, with 80% of patients in 
the highest risk group experiencing an unfavourable outcome. 
However, only 6% of patients were identified as being at high 
risk. Risk mitigation strategies aimed at this subgroup would 
only reach a minority of patients with a future clinical event and 
would therefore have limited impact on overall survival in the 
HDV population.
In conclusion, the study by Palom et al paints a sobering picture 
of the state of the art of HDV management: diagnoses are frequently 
made when cirrhosis is already present, identifying patients at high‐
est risk for adverse outcome remains challenging, and current ther‐
apies have limited response rates. Novel treatment options that can 
also be used in patients with advanced liver disease are therefore 
urgently needed.
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